Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing JDQ443 with docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer is ongoing/activ…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]
Phase 3 trial evaluating Zongertinib (BI 1810631) for advanced non-small cell lung cancer with HER2 mutations; currently active/not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) [Phase 3]
Phase 3 trial evaluating Acasunlimab plus Pembrolizumab vs. standard of care Docetaxel in PD-L1-positive non-small cell lung cancer is activ…
-
CLINICAL_TRIALS trial_result · 2026-05-01Clinical Trial Update: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance in advanced/metastatic non-small cell …
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Results: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]
Phase 3 trial results evaluating cemiplimab in combination with platinum-based chemotherapy for non-small cell lung cancer have been complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]
Phase 3 trial evaluating cemiplimab with platinum-based chemotherapy in non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]
Phase 3 trial evaluating Zongertinib (BI 1810631) versus standard treatment for advanced non-small cell lung cancer with HER2 mutations (Lun…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating first-line anti-PD-1/PD-L1 mAb with chemotherapy and bronchoscopy-assisted therapy in advanced non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) [Phase 3]
A Phase 3 trial evaluating adagrasib with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy in untreated KRA…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms [Phase 2, Phase 3]
Phase 2/3 pharmacogenomics trial evaluating alectinib with SNPs in patients with non-small cell lung cancer; currently active but not recrui…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status [Phase 2]
Phase 2 trial update of adagrasib in KRASG12C-mutant non-small cell lung cancer (Stage IV) in elderly or poor performance status patients is…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations [Phase 3]
Phase 3 trial of poziotinib in previously treated locally advanced or metastatic non-small cell lung cancer with HER2 exon 20 mutations is s…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating immunotherapy or targeted therapy with or without stereotactic radiosurgery for brain metastases from melanoma or…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In [Phase 3]
Phase 3 trial evaluating N-803 plus tislelizumab or prior failed immune checkpoint inhibitor with docetaxel vs docetaxel alone in advanced/m…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms [Phase 2, Phase 3]
Phase 2/3 clinical trial update investigating alectinib in relation to pharmacogenomics SNPs in non-small cell lung cancer. The study is act…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations [Phase 1, Phase 2]
This document reports an ongoing first-in-human study of STX-721/PFL-721 in locally advanced or metastatic non-small cell lung cancer with E…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Natural Killer Cells and Bortezomib to Treat Cancer [Phase 1]
This Phase 1 clinical trial update reports on the combination of natural killer cells and bortezomib for several cancers, and the study has …
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment [Phase 2]
Phase 2 clinical trial evaluating safety and preliminary efficacy of Pumitamig (BNT327) in combination with chemotherapy for first-line or s…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Whole Genomic Landscape of Advanced EGFR-mutant NSCLC [NA]
This entry notes an active-not-recruiting clinical trial investigating the whole genomic landscape of advanced EGFR-mutant non-small cell lu…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) [Phase 3]
A Phase 3 clinical trial update evaluating erlotinib hydrochloride as adjuvant therapy after complete surgical resection for stage IB-IIIA n…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC [Phase 1]
A Phase 1 trial evaluating ORIC-114 in combination with subcutaneous amivantamab for EGFR exon 20 insertion-mutant non-small cell lung cance…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: AZD9291 in Combination With Ascending Doses of Novel Therapeutics [Phase 1]
Phase 1 study evaluating AZD9291 (osimertinib) in combination with escalating doses of novel therapies for advanced non-small cell lung canc…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
This clinical trial update from the National Cancer Institute describes tissue procurement and a natural history study enrolling people with…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer [Phase 3]
Global Phase III trial evaluating rilvegostomig or pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cel…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors [Phase 3]
A Phase 3 clinical trial comparing ONC-392 to docetaxel in metastatic Non-Small Cell Lung Cancer that progressed on PD-1/PD-L1 inhibitors. T…